Zayid Al-Aly
Zayid Al-Aly is a physician-scientist; he directs the Clinical Epidemiology Center and serves as the Chief of Research and Development Service at the VA Saint Louis Health Care System. He is a senior clinical epidemiologist at Washington University in Saint Louis. He has several research interests including pharmacoepidemiology, environmental epidemiology, global health, and most recently short- and long-term effects of COVID-19 on health outcomes.
He led work which provided systematic characterization of the post-acute sequelae of SARS-CoV-2 infection (also called Long Covid) and subsequently characterization of the increased risks of cardiovascular disease, neurologic disorders, diabetes, dyslipidemia, kidney disease, and gastrointestinal disorders following SARS-CoV-2 infection. His laboratory was the first to produce evidence characterizing the effects of vaccines on Long Covid, the health consequences of repeated infections with SARS-CoV-2, and the effect of antivirals on the short- and long-term outcomes of SARS-CoV-2 infection.
He co-chaired the U.S. Biden-Harris Administration committee that developed the National Research Action Plan for Long Covid. He serves on the U.S. Government Interagency Long Covid Coordination Council. He currently serves on a consensus committee at the U.S. National Academy of Sciences, Engineering, and Medicine looking at the long-term health effects stemming from COVID-19 and their implications for the U.S. Social Security Administration. He is also a member of the White House Cancer Moonshot Task Force for data and innovation.
A Physician Explains GLP-1s’ Biggest Potential Side Effect: A Rare But Serious Eye Condition
What is the risk for the millions of people worldwide who take GLP-1 medications?


